Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies ...

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug ...

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Biogen partners with City Therapeutics to develop select novel RNAi-based therapies: Cambridge, Massachusetts Thursday, May 29, 2025, 10:00 Hrs [IST] Biogen Inc, a leading biotech ...

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments.

City will receive $46 million from Biogen under the alliance. Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug.

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi ...

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies targeting serious diseases. Under the agreement, City Therapeutics will use ...

Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop novel RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics will ...